Proteome Sciences PLC Milestone towards Single Cell Proteomics services (6832U)
2022年8月3日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMPRM
RNS Number : 6832U
Proteome Sciences PLC
03 August 2022
3 August 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Proteome Sciences completes milestone towards launch of Single
Cell Proteomics services
Proteome Sciences is pleased to announce that the Company has
completed the next milestone towards the launch of Single Cell
Proteomics services, which will be known as SysQuant(R) SCP, with
the installation of a cellenONE(R) (Cellenion, France) platform
that allows the semi-automated preparation of up to 2,700 cells per
week. The Company anticipates that most commercial projects will
require analysis of 500 - 1,000 cells using TMTpro(TM)
multiplexing, and it will be able to perform 1-2 such studies per
week. Working with such small samples is challenging and will be
beyond the means of many academic and industrial research groups.
The Company believes its employees' experience as inventors and
manufacturers of TMT(R) and TMTpro(TM) reagents gives the Company
unique insights into their use in this complex setting.
Following initial experiments, the Company expects coverage of
between 1,000 and 1,500 proteins per cell. The Company expects to
complete the platform and process validation in Q3 2022 and then
launch the dedicated multiplex SysQuant(R) SCP services before the
end of the year. This complements the expansion of the Company's
mass spectrometer platforms late last year and will establish
Proteome Sciences as the premier provider of single cell
proteomics.
Commenting on the development of SysQuant(R) SCP, Dr. Ian Pike,
Chief Scientific Officer said:
"It is clear that the demand for a standardized service is
growing rapidly. The use of TMTpro(TM) reagents is greatly
enhancing coverage in studies of 100s of individual cells and
provides the throughput necessary for large studies needed in
pharmaceutical research. By isolating and labelling each cell with
TMTpro(TM) tags and then mixing to make a more concentrated sample
on the cellenONE(R) platform, we can explore the true diversity of
functional biology in every disease, with the potential to identify
new drug targets and diagnostic biomarkers. The system provides the
level of throughput required for our initial plans to launch a
SysQuant(R) SCP service and is scalable to rapidly increase
capacity as the market opportunity grows. This is a major step in
the process and we have further exciting developments for single
cell proteomics planned for the future".
For further information:
Proteome Sciences plc
Dr Mariola Soehngen, Chief Executive Officer &
Dr Ian Pike, Chief Scientific Officer Tel: +44 (0)20 7043 2116
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R) MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in Cobham, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBRGDIDGGDGDD
(END) Dow Jones Newswires
August 03, 2022 02:00 ET (06:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
過去 株価チャート
から 11 2024 まで 12 2024
Proteome Sciences (AQSE:PRM.GB)
過去 株価チャート
から 12 2023 まで 12 2024